Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Abhishek Maiti, Sean M. Post, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Allison Pike, Hyunsoo Hwang, Xuelin Huang, Michael Andreeff, Farhad Ravandi, Jinho CHOI, Hyunji Ahn, Jeongjun Kim, Kiyean Nam, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2024-202834

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Blood (2023) 142 (Supplement 1): 58.

https://doi.org/10.1182/blood-2023-182337

Published: 2023

Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2023-182901

Published: 2023

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Blood (2018) 132 (Supplement 1): 905.

https://doi.org/10.1182/blood-2018-99-116078

Published: 2018

Journal Articles

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 815.

https://doi.org/10.1182/blood.V130.Suppl_1.815.815

Published: 2017

Journal Articles

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Allison Pike, RN, Julie Huynh-Lu, Physician Assistant, Madeleine Nguyen-Cao, Physician Assistant, Xuemei Wang, Lingsha Zhou, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 255.

https://doi.org/10.1182/blood.V130.Suppl_1.255.255

Published: 2017

Journal Articles

Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2016) 128 (22): 1067.

https://doi.org/10.1182/blood.V128.22.1067.1067

Published: 2016

Journal Articles

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Elias J. Jabbour, MD, Allison Pike, RN, Kate J Newberry, PhD, Lingsha Zhou, Sherry Pierce, BSN, BA, Xuemei Wang, MS, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 478.

https://doi.org/10.1182/blood.V128.22.478.478

Published: 2016

Journal Articles

Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nitin Jain, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Koichi Takahashi, MD, Christopher B. Benton, MD, Allison Pike, RN, Sherry Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 2817.

https://doi.org/10.1182/blood.V128.22.2817.2817

Published: 2016

Journal Articles

Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial

Paul B. Koller, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Jad Chahoud, MD, Allison Pike, RN, Mark Brandt, BS, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Elias Jabbour

Blood (2015) 126 (23): 2508.

https://doi.org/10.1182/blood.V126.23.2508.2508

Published: 2015

Journal Articles

Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nitin Jain, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Allison Pike, RN, Carol Bivins, RN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2014) 124 (21): 5283.

https://doi.org/10.1182/blood.V124.21.5283.5283

Published: 2014

NARROW

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial

Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only